2. Anti-infection Stem Cell/Wnt MAPK/ERK Pathway Apoptosis Metabolic Enzyme/Protease
  3. Fungal ERK JNK p38 MAPK Apoptosis Mitochondrial Metabolism
  4. Meptyldinocap

Meptyldinocap (2,4-DNOPC) is a fungicide and cytotoxic agent that acts against powdery mildew. Meptyldinocap upregulates the phosphorylation levels of ERK1/2, JNK and p38. Meptyldinocap induces apoptosis and endoplasmic reticulum stress, disrupts calcium homeostasis, inhibits cell proliferation and migration, downregulates the expression of proliferation- and pregnancy-related genes, and triggers mitochondrial dysfunction. Meptyldinocap can be used in studies related to powdery mildew and implantation failure.

For research use only. We do not sell to patients.

Meptyldinocap

Meptyldinocap Chemical Structure

CAS No. : 131-72-6

Size Price Stock Quantity
Oil + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Oil
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Meptyldinocap:

Meptyldinocap Related Antibodies

Top Publications Citing Use of Products

View All ERK Isoform Specific Products:

View All Isoforms
ERK ERK1 ERK2 ERK5 ERK8

View All JNK Isoform Specific Products:

View All Isoforms
JNK1 JNK2 JNK3 JNK

View All p38 MAPK Isoform Specific Products:

View All Isoforms
p38 MAPK Akt1 p38α p38β MAPK13 p38δ p38γ

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Meptyldinocap (2,4-DNOPC) is a fungicide and cytotoxic agent that acts against powdery mildew. Meptyldinocap upregulates the phosphorylation levels of ERK1/2, JNK and p38. Meptyldinocap induces apoptosis and endoplasmic reticulum stress, disrupts calcium homeostasis, inhibits cell proliferation and migration, downregulates the expression of proliferation- and pregnancy-related genes, and triggers mitochondrial dysfunction. Meptyldinocap can be used in studies related to powdery mildew and implantation failure[1][2].

In Vitro

Meptyldinocap (10-500 nM; 48 h) reduces the viability of pTr and pLE cells in a concentration-dependent manner[2].
Meptyldinocap (150 nM; 48 h) reduces the expression levels of proliferation-related genes PCNA and CDK1 in pTr and pLE cells[2].
Meptyldinocap (150 nM; 24 h) reduces the protein expression levels of proliferation markers PCNA and Ki67 in pTr and pLE cells[2].
Meptyldinocap (50-150 nM; 48 h) increases the proportions of early and late apoptosis in pTr cells; after 48 h of treatment, the 150 nM concentration increases the proportion of early apoptosis in pLE cells, while the 100 and 150 nM concentrations increase the proportion of late apoptosis in pLE cells[2].
Meptyldinocap (50-150 nM; 48 h) induces concentration-dependent cell cycle arrest in pTr cells[2].
Meptyldinocap (150 nM; 24 h) significantly reduces the maximal mitochondrial respiration level of pTr cells; after 24 h of treatment, it shows a non-significant trend of decreased mitochondrial respiration parameters in pLE cells[2].
Treatment with Meptyldinocap (150 nM; 48 h) significantly reduces the mitochondrial membrane potential (MMP) of pTr cells and pLE cells to 207.5% and 271.1%, respectively[2].
Meptyldinocap (50-150 nM; 48 h) upregulates the expression of endoplasmic reticulum stress-related proteins GRP78 and p-eIF2α in pTr cells[2].
Meptyldinocap (50-150 nM; 48 h) reduces the cytoplasmic calcium concentration in pTr cells and pLE cells, thereby disrupting calcium homeostasis[2].
Meptyldinocap (50-150 nM; 30 min) upregulates the phosphorylation levels of ERK1/2, JNK and p38 in pTr cells, thereby altering the MAPK signaling cascade[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Meptyldinocap Related Antibodies

Cell Viability Assay[2]

Cell Line: porcine trophectoderm (pTr) cells, porcine endometrial luminal (pLE) cells
Concentration: 10, 20, 50, 100, 200, 500 nM
Incubation Time: 48 h
Result: Decreased cell viability significantly at 100, 200, and 500 nM in both cell lines.
Reduced cell viability to 50% between 100 and 200 nM for both cell lines.

Real Time qPCR[2]

Cell Line: porcine trophectoderm (pTr) cells, porcine endometrial luminal (pLE) cells
Concentration: 150 nM
Incubation Time: 48 h
Result: Reduced PCNA expression to 0.31-fold lower in pTr cells and 0.20-fold lower in pLE cells compared to vehicle-treated controls.
Reduced CDK1 expression to 0.11-fold lower in both cell types compared to vehicle-treated controls.

Immunofluorescence[2]

Cell Line: porcine trophectoderm (pTr) cells, porcine endometrial luminal (pLE) cells
Concentration: 150 nM
Incubation Time: 24 h
Result: Reduced PCNA expression in both cell lines.
Reduced the signal intensity of Ki67 in pTr and pLE cells.

Apoptosis Analysis[2]

Cell Line: porcine trophectoderm (pTr) cells, porcine endometrial luminal (pLE) cells
Concentration: 50, 100, 150 nM
Incubation Time: 48 h
Result: Increased early apoptotic pTr cells to 294.1%, 310.8%, and 310.8% across 50, 100, 150 nM respectively.
Increased late apoptotic pTr cells to 156.6%, 220.9%, and 225.3% across 50, 100, 150 nM respectively.
Showed non-significant increases in early apoptotic pLE cells at 50 and 100 nM, and a significant increase to 310.8% at 150 nM.
Showed non-significant increase in late apoptotic pLE cells at 50 nM, significant increases at 100 nM and 150 nM (225.3%).

Cell Cycle Analysis[2]

Cell Line: porcine trophectoderm (pTr) cells, porcine endometrial luminal (pLE) cells
Concentration: 50, 100, 150 nM
Incubation Time: 48 h
Result: Induced G1-arrest in pTr cells at 50 nM (G1-phase proportion increased to 80.9%) and 100 nM (G1-phase proportion increased to 84.7%), and G2-arrest at 150 nM (G2-phase proportion increased to 25.4%).
Decreased S-phase cell proportion significantly in pTr cells at 50 and 100 nM.
Induced G1-arrest in pLE cells at all tested concentrations (G1-phase proportion increased to 75.1%, 77.9%, and 77.2% respectively), with significant decreases in S-phase cells at all concentrations.
Reduced CCNB1 expression in pTr cells to 0.73-fold, 0.14-fold, 0.08-fold lower at 50, 100, 150 nM respectively; reduced CCNB1 expression in pLE cells to 0.40-fold and 0.12-fold lower at 100 and 150 nM respectively (no significant change at 50 nM).
Reduced CCND1 expression in pTr cells to 0.76-fold, 0.73-fold, 0.90-fold lower at 50, 100, 150 nM respectively; showed no significant alteration in CCND1 expression in pLE cells.

Western Blot Analysis[2]

Cell Line: porcine trophectoderm (pTr) cells, porcine endometrial luminal (pLE) cells
Concentration: 50, 100, 150 nM
Incubation Time: 48 h
Result: Upregulated GRP78 expression to 233.8%, 348.2%, and 678.4% at 50, 100, 150 nM respectively in pTr cells.
Upregulated p-eIF2α expression to 189.5%, 198.0%, and 214.2% at 50, 100, 150 nM respectively in pTr cells.
Upregulated GRP78 expression to 199.9% at 150 nM in pLE cells.
Upregulated p-eIF2α expression to 165.7%, 199.8%, and 230.9% at 50, 100, 150 nM respectively in pLE cells.

Western Blot Analysis[2]

Cell Line: porcine trophectoderm (pTr) cells, porcine endometrial luminal (pLE) cells
Concentration: 50, 100, 150 nM
Incubation Time: 30 min
Result: Upregulated phospho-ERK1/2 levels to 125.5%, 139.8%, and 149.8% at 50, 100, 150 nM respectively in pTr cells.
Upregulated phospho-JNK levels to 130.4%, 135.9%, and 149.8% at 50, 100, 150 nM respectively in pTr cells.
Upregulated phospho-p38 levels to 124.5%, 150.9%, and 159.8% at 50, 100, 150 nM respectively in pTr cells.
Upregulated phospho-ERK1/2 levels to 159.4% and 175.0% at 100 and 150 nM respectively in pLE cells.
Upregulated phospho-JNK levels to 156.6% and 151.8% at 100 and 150 nM respectively in pLE cells.
Upregulated phospho-p38 levels to 181.7%, 163.5%, and 171.1% at 50, 100, 150 nM respectively in pLE cells.
Molecular Weight

364.39

Formula

C18H24N2O6
CAS No.
Appearance

Oil

Color

Light yellow to yellow

SMILES

C/C=C/C(OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1C(C)CCCCCC)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Pure form -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : ≥ 150 mg/mL (411.65 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 100 mg/mL (274.43 mM; Need ultrasonic)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.7443 mL 13.7216 mL 27.4431 mL
5 mM 0.5489 mL 2.7443 mL 5.4886 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (6.86 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: 2.5 mg/mL (6.86 mM); Suspended solution; Need ultrasonic

    This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.91%

SDS (623 KB)

COA (248 KB) HNMR (253 KB) RP-HPLC (257 KB) LCMS (119 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
Ethanol / DMSO 1 mM 2.7443 mL 13.7216 mL 27.4431 mL 68.6078 mL
5 mM 0.5489 mL 2.7443 mL 5.4886 mL 13.7216 mL
10 mM 0.2744 mL 1.3722 mL 2.7443 mL 6.8608 mL
15 mM 0.1830 mL 0.9148 mL 1.8295 mL 4.5739 mL
20 mM 0.1372 mL 0.6861 mL 1.3722 mL 3.4304 mL
25 mM 0.1098 mL 0.5489 mL 1.0977 mL 2.7443 mL
30 mM 0.0915 mL 0.4574 mL 0.9148 mL 2.2869 mL
40 mM 0.0686 mL 0.3430 mL 0.6861 mL 1.7152 mL
50 mM 0.0549 mL 0.2744 mL 0.5489 mL 1.3722 mL
60 mM 0.0457 mL 0.2287 mL 0.4574 mL 1.1435 mL
80 mM 0.0343 mL 0.1715 mL 0.3430 mL 0.8576 mL
100 mM 0.0274 mL 0.1372 mL 0.2744 mL 0.6861 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Meptyldinocap Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Meptyldinocap131-72-62,4-DNOPCFungalERKJNKp38 MAPKApoptosisMitochondrial MetabolismExtracellular signal regulated kinasesc-Jun N-terminal kinasepTr cellspLE cellsCDK1Erysiphe necatorp38mitogen-activated protein kinaseERK1/2PCNAKi67Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Meptyldinocap
Cat. No.:
HY-17522
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (623 KB) Français - FR (623 KB) Deutsch - DE (623 KB) Norwegian - NO (623 KB) Español - ES (623 KB) Swedish - SV (623 KB) Italian - IT (623 KB) Korean - KR (623 KB) Portuguese - PT (623 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.